Navigation Links
Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
Date:9/15/2009

Current therapeutic options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of antibiotic administration.

Primary risk factors for CDI include broad-spectrum antibiotic use, advanced age (over 65), emerging hyper-virulent strains (BI /NAP1/027, 078, 001) of C. difficile, and previous exposure to CDI that lead to recurrence. Higher incidence, increased treatment failures, and recurrence with standard therapies have resulted in greater awareness and concern of CDI among medical professionals and public health officials.

About Fidaxomicin (OPT-80)

Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... -- The U.S. Food and Drug Administration (FDA) Endocrinologic ... yes, 4 no, and 1 abstention that AstraZeneca has ... support the use of CRESTOR® (rosuvastatin calcium) in individuals ... or equal to 50 years, women greater than or ... 130 mg/dL; hsCRP greater than or equal to 2.0 ...
(Date:12/15/2009)... MONICA, Calif., Dec. 15 Dakim, Inc. and ... Thanks for Loved Ones, Brain Health Contest, designed to ... symptoms of dementia and Alzheimer,s disease. All five winners ... product designed specifically to help seniors preserve their brain ... kind in senior living communities across the country. ...
(Date:12/15/2009)... Flextronics (Nasdaq: FLEX ) today ... announced acquisition of SloMedical S.R.O., a leading ... from tubing sets to complex devices for ... provides a broad set of capabilities to ... Terms of the deal were not disclosed. ...
Breaking Medicine Technology:Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 55 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Flextronics Completes SloMedical Acquisition 2Medical Heroin Helps Treatment Resistant Addicts 54920 1Medical Heroin Helps Treatment Resistant Addicts 54920 2Medical Heroin Helps Treatment Resistant Addicts 54920 3Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 1Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 2Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 3Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 4Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 5Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 6Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 7Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 8Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 9Roche and InterMune Initiate Phase 2b Clinical Trial of RG7227 ITMN 191 in Patients With Chronic Hepatitis C 54915 10LSUHSC research discovers new targets for treatment of invasive breast cancer 54910 1LSUHSC research discovers new targets for treatment of invasive breast cancer 54910 2
... 6 Four studies highlighting late-breaking research advances in the ... today at the 50th Annual Meeting of the American Society ... , Results from a study examining the ability ... in the inner lining of blood vessels, in patients with ...
... FRANCISCO, Dec. 6 Researchers today report that ... erythropoiesis-stimulating agents (ESAs), a significantly greater proportion of ... who received ESAs needed blood transfusions and utilized ... patients who received ESAs prior to implementation of ...
Other Medicine Technology:Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 2Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 3Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 4Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 5Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 6Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 7Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 8Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting 9Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion 2Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion 3Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion 4Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion 5Observational Study Finds Changes in Medicare Reimbursement for Erythropoiesis-Stimulating Agents Associated With Increased Need for Blood Transfusion 6
(Date:12/15/2009)... doses have lower strength than needed for protection, CDC ... 800,000 children,s doses of H1N1 swine flu vaccine have ... have lost some potency, federal health officials said Tuesday. ... and Prevention, the company,s routine testing of the vaccine ... found that four batches had lower than required potency ...
(Date:12/15/2009)... program will train advocates to be leaders in ... developed with support from experts in online learning, ... WASHINGTON, Dec. 15 ONE ... accepting applications for the first-ever "Malaria Griots" program, ... educate participants to become leaders in the fight ...
(Date:12/15/2009)... N.Y., Dec. 15 Team In Training ... charity sports training program, has reached ... support blood cancer research and patient services. ,, ... the pre-eminent charity endurance sports training program, preparing ... half marathon, triathlon, 100-mile century cycle ride or ...
(Date:12/15/2009)... The new compact LifeSpan TR200 folding treadmill, ... ), was highly praised by treadmill review groups ... The compact TR200 folding treadmill received awards for Best ... $1000. ,, The compact LifeSpan TR200 treadmill is ... spaces. "This category buster is a very compact treadmill ...
(Date:12/15/2009)... known to reduce depression and fatigue in people struggling ... effect stems from an individual,s sense of mastery over ... achieve certain physical goals. , The study appears ... base our arguments on fatigue being a symptom of ... community health at the University of Illinois and lead ...
Breaking Medicine News(10 mins):Health News:Large Recall of Children's Swine Flu Vaccine 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 2Health News:ONE and Malaria No More Launch 'Malaria Griots' 3Health News:ONE and Malaria No More Launch 'Malaria Griots' 4Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2Health News:Mastery of physical goals lessens disease-related depression and fatigue 2
... The Foundation,for Taxpayer and Consumer Rights (FTCR) ... California state Senate intended to reform the state ... introduced by Sen. Sheila Kuehl (D-23) and Sen.,George ... residents,will have access to therapies and drugs made ...
... Study says doctors overestimated in-hospital mortality by 51% , , ... that in-hospital deaths from heart disease are over-reported in ... the highest reported heart disease death rates in the ... among residents of the city is comparable to the ...
... spine, back and neck surgeon at Rush University Medical ... who underwent surgery for spinal stenosis showed significantly more ... were treated nonsurgically. The study findings were published in ... Spinal stenosis involves a narrowing of a passage in ...
... LeMaitre Vascular,Inc. (Nasdaq: LMAT ) announced today ... year financial results on March 4, 2008, after the ... conference call will be,hosted the same day at 5:00 ... internet., Interested participants may listen to the live ...
... says measurement underestimates true glucose control in hemodialysis patients ... standard test for measuring blood sugar control in people ... hemodialysis, a U.S. study finds. , Hemodialysis, used to ... circulating it through an artificial kidney machine. , ...
... Feb. 22 , What: The Sister to Sister Women,s Heart ... heart screenings to measure women,s cholesterol, blood ... of family health history. Potential ... on-site. Medical counselors will explain the results and ...
Other Medicine News:Health News:Consumer Group Welcomes Introduction of Stem Cell Agency Oversight Bill 2Health News:Heart Disease Deaths Over-Reported in New York City 2Health News:Current Blood Sugar Control Test Results 'Inaccurate' 2Health News:2008 Women's Heart Health Fair Offers Free Screenings, Advice for Baltimore Women 2
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
Medicine Products: